{
  "ticker": "LLY",
  "target_date": "2025-04-16",
  "actual_date": "2025-04-16",
  "collected_at": "2025-12-08T11:39:00.793748",
  "price": {
    "open": 751.34,
    "high": 751.99,
    "low": 726.18,
    "close": 730.7162475585938,
    "volume": 3302600,
    "change_1d_pct": -2.94,
    "change_7d_pct": 1.54,
    "change_30d_pct": -20.95
  },
  "technicals": {
    "rsi_14": 32.9,
    "sma_20": 782.94,
    "sma_50": 830.74,
    "macd": -28.188,
    "macd_signal": -25.347,
    "macd_histogram": -2.841,
    "bb_upper": 880.84,
    "bb_lower": 685.04,
    "price_vs_sma20_pct": -6.67,
    "price_vs_sma50_pct": -12.04,
    "volume_ratio": 0.89
  },
  "fundamentals": {
    "market_cap": 889361334272,
    "pe_ratio": 48.60779,
    "forward_pe": 43.781334,
    "price_to_book": 37.3526,
    "price_to_sales": 14.967424,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.78,
    "pct_from_52w_low": 59.04
  },
  "macro": {
    "spy": {
      "price": 522.66,
      "change_1d_pct": -2.22,
      "change_7d_pct": 5.88
    },
    "vix": {
      "level": 32.64,
      "signal": "HIGH_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.28
    },
    "dollar_index": {
      "level": 99.38
    },
    "gold": {
      "price": 3326.6
    },
    "regime": "SIDEWAYS"
  },
  "news": [
    {
      "headline": "Novo Nordisk A/S (NVO): A Bull Case Theory",
      "source": "Yahoo",
      "datetime": 1744828655,
      "summary": "We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls\u2019 thesis on NVO. Novo Nordisk A/S (NVO)\u2019s share was trading at $64.49 as of April 15th. NVO\u2019s trailing and forward P/E were 18.76 and 15.41 respectively according to Yahoo Fina",
      "url": "https://finnhub.io/api/news?id=8ebbc7aef4cd89beb7251c970ee5c1e9140e79ff8b6347437e5e4bbc87faa893"
    },
    {
      "headline": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "source": "MarketWatch",
      "datetime": 1744821060,
      "summary": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=9b645c5fd8c6923c565a3733437122f2701df75c29917d0249496447af9444e4"
    },
    {
      "headline": "IYH: Healthcare Dashboard For April",
      "source": "SeekingAlpha",
      "datetime": 1744814463,
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ef60e7fe50c851812342eddac8f56058cf17e7e5c0696e76992c679d592b9289"
    },
    {
      "headline": "The GLP-1 drug shortage is over. What\u2019s next for the compounders?",
      "source": "Yahoo",
      "datetime": 1744814353,
      "summary": "Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide offerings.",
      "url": "https://finnhub.io/api/news?id=1809330ab10d34b75abdb2ef64fb78e70d8d82cca84af571019c6534342a85ff"
    },
    {
      "headline": "Teladoc: Back In The Doldrums After Another Tough Year (Rating Downgrade)",
      "source": "SeekingAlpha",
      "datetime": 1744804123,
      "summary": "",
      "url": "https://finnhub.io/api/news?id=699430856a9543401900d18a05229bb2ba87fe9f6763251f2f51a68b4c2c10b9"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742416067.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000103/xslF345X05/wk-form4_1742416067.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415936.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000101/xslF345X05/wk-form4_1742415936.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415842.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000099/xslF345X05/wk-form4_1742415842.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415665.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000097/xslF345X05/wk-form4_1742415665.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415462.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000095/xslF345X05/wk-form4_1742415462.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}